Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 13;226(5):808-811.
doi: 10.1093/infdis/jiac063.

Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages

Tommy Nyberg  1 , Katie Harman  2 , Asad Zaidi  2 , Shaun R Seaman  1 , Nick Andrews  3 , Sophie G Nash  2 , Andre Charlett  4 , Jamie Lopez Bernal  3 , Richard Myers  5 , Natalie Groves  5 , Eileen Gallagher  5 , Saheer Gharbia  6 , Meera Chand  5 , Simon Thelwall  2 , Daniela De Angelis  1 , Gavin Dabrera  2 , Anne M Presanis  1
Affiliations

Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages

Tommy Nyberg et al. J Infect Dis. .

Abstract

To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR = 0.85; 95% confidence interval [CI], .77-.94), hospital admission or emergency care attendance (aHR = 0.87; 95% CI, .81-.94), and COVID-19 mortality (aHR = 0.85; 95% CI, .71-1.03). The results indicate that the risks of hospitalization and mortality are similar or lower for AY.4.2 compared to cases with other delta sublineages.

Keywords: AY.4.2; COVID-19; SARS-CoV-2; VUI-21OCT-01; hospitalization; mortality.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. G. D. declares that his employer, UK Health Security Agency, previously known as Public Health England, received funding from GlaxoSmithKline for a research project related to influenza antiviral treatment. This preceded and had no relation to COVID-19, and G. D. had no role in and received no funding from the project. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

    1. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefings. https://www.gov.uk/government/publications/investigation-of-sars-cov-2-v.... Accessed 8 February 2022.
    1. Twohig KA, Nyberg T, Zaidi A, et al. . Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis 2022; 22:35–42. - PMC - PubMed
    1. Seaman SR, Nyberg T, Overton CE, Pascall D, Presanis AM, De Angelis D.. Adjusting for time of infection or positive test when estimating the risk of a post-infection outcome in an epidemic. medRxiv, doi: 10.1101/2021.08.13.21262014, 18. August 2021, preprint: not peer reviewed. - DOI - PMC - PubMed
    1. Chadeau-Hyam M, Eales O, Bodinier B, et al. . REACT-1 round 15 final report: increased breakthrough SARS-CoV-2 infections among adults who had received two doses of vaccine, but booster doses and first doses in children are providing important protection. medRxiv, doi: 10.1101/2021.12.14.21267806, 16. December 2021, preprint: not peer reviewed. - DOI
    1. Volz E, Mishra S, Chand M, et al. . Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 2021; 593:266–9. - PubMed

Publication types

Supplementary concepts